Posts By :

admin

Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors
Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 01, 2020 (GLOBE NEWSWIRE)

Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Aug. 10, 2020 (GLOBE NEWSWIRE)

Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC
Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC 2560 1707 Diffusion Pharmaceuticals Inc.

Guidance being incorporated into global study protocol Enrollment of first patient now expected in August…

Diffusion Pharmaceuticals Files Ind for International Phase 1b/2b COVID-19 Clinical Program With Tsc
Diffusion Pharmaceuticals Files Ind for International Phase 1b/2b COVID-19 Clinical Program With Tsc 2560 1707 Diffusion Pharmaceuticals Inc.

Phase 1b dosing expected to begin this month Data read-out expected later this quarter CHARLOTTESVILLE,…

Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of Tsc in COVID-19 Patients
Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of Tsc in COVID-19 Patients 2560 1707 Diffusion Pharmaceuticals Inc.

Dosing expected to begin in Q2 2020 with first data in Q3 2020 Trial expected…

Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed Tsc COVID-19 Clinical Trial Program
Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed Tsc COVID-19 Clinical Trial Program 2560 1707 Diffusion Pharmaceuticals Inc.

First U.S. study to feature double-blinded, controlled, randomized trial design with safety and oxygenation endpoints…

Diffusion Pharmaceuticals Expands Clinical Trial Program of Tsc for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases
Diffusion Pharmaceuticals Expands Clinical Trial Program of Tsc for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases 2560 1707 Diffusion Pharmaceuticals Inc.

Planned study features noted principal investigator, regulatory flexibility, and immediate availability of patients CHARLOTTESVILLE, Va.,…

Back to top